| Effects of carboxymethyl-glucan from Saccharomyces cerevisiae on the peripheral blood cells of patients with advanced prostate cancer |
Authors: Marciane Magnani, Raul Hernan Castro-Gomez, Mateus Nobrega Aoki, Emerson Pereira Gregório, Farid Libos, Maria Angelica Ehara Watanabe |
Affiliations: Departamento de Ciência e Tecnologia de Alimentos, Universidade Estadual de Londrina, Londrina, Paraná, Brasil, Departamento de Ciências Patológicas, Universidade Estadual de Londrina, Londrina, Paraná, Brasil, Instituto do Câncer de Londrina, Londrina, Paraná, Brasil |
Published online on: Tuesday, July 20, 2010 |
Doi: 10.3892/etm.2010.121 |
Pages: 859-862 |
Abstract:Carboxymethyl-glucan (CM-G) is a water-soluble derivative of β(1-3)(1-6) glucan that is well known for its immunostimulant and hematopoiesis-enhancing activities. In this clinical trial, we assessed the effects of oral CM-G administration on the peripheral blood cells of patients with advanced prostate cancer, and examined its ability to alter hepatic and renal function. After CM-G administration, the total leukocyte count increased significantly (p≤0.02), with no associated changes in the lifestyle habits of the patients. A significant increase (p≤0.001) was also observed for red blood cell, hematocrit, hemoglobin and platelet counts. No changes were observed in hepatic or renal function after CM-G administration, and no side effects associated with its use were recorded. These results suggest that using CM-G as an adjuvant to cancer treatment may improve the health parameters of prostate cancer patients. |
|
|
|
|
